Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

natco pharma limited - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus tablets are indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. everolimus tablets are indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (pnet) with unresectable, locally advanced or metastatic disease. everolimus tablets are indicated for the treatment of adult patients with progressive, well-differentiated, non-functional net of gastrointestinal (gi) or lung origin with unresectable, locally advanced or metastatic disease. limitations of use:  everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors [see clinical studies (14.2)] . everolimus tablets are indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenib. everolimus tablets are indicated for the treatment of adult patients wi

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

natco pharma limited - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus is indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant [see clinical studies (14.1)]. everolimus is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. therapeutic drug monitoring (tdm) of everolimus and cyclosporine is recommended for all patients receiving these products [see dosage and administration (2.2, 2.3)] . everolimus is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. everolimus is to be administered no earlier than 30 days post-transplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids [see warnings and precautions (5.5), clinical studies (14.2)]. tdm of everolimus and tacrolimus is recommended for all patients receiving these products [see dosage and administration (2.3, 2.5)]. the safety and efficacy of everolimus has not been estab

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus tablets for oral suspension are indicated in adult and pediatric patients aged 1 year and older with tsc for the treatment of sega that requires therapeutic intervention but cannot be curatively resected. everolimus tablets for oral suspension are indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with tsc-associated partial-onset seizures. everolimus tablets for oral suspension are contraindicated in patients with clinically significant hypersensitivity to everolimus or to other rapamycin derivatives [see warnings and precautions (5.3)] . based on animal studies and the mechanism of action [see clinical pharmacology (12.1)] , everolimus tablets for oral suspension can cause fetal harm when administered to a pregnant woman. there are limited case reports of afinitor use in pregnant women; however, these reports are not sufficient to inform about risks of birth defects or miscarriage. in animal studies, everolimus caused embryo-fetal toxicities in rats when

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

ascend laboratories, llc - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus tablets are indicated for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant [see clinical studies (14.1) ] everolimus tablets are to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. therapeutic drug monitoring (tdm) of everolimus tablets and cyclosporine is recommended for all patients receiving these products. [see dosage and administration (2.2, 2.3) ] everolimus tablets are indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. everolimus tablets are to be administered no earlier than 30 days post-transplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids [see warnings and precautions (5.5), clinical studies (14.2) ]. therapeutic drug monitoring (tdm) of everolimus tablets and tacrolimus is recommended for all patients receiving these products [see dosage and adm

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - everolimus (unii: 9hw64q8g6g) (everolimus - unii:9hw64q8g6g) - everolimus 5 mg - afinitor® is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. afinitor is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (pnet) with unresectable, locally advanced or metastatic disease. afinitor is indicated for the treatment of adult patients with progressive, well-differentiated, non-functional net of gastrointestinal (gi) or lung origin with unresectable, locally advanced or metastatic disease. limitations of use: afinitor is not indicated for the treatment of patients with functional carcinoid tumors [see clinical studies (14.2)] . afinitor is indicated for the treatment of adult patients with advanced rcc after failure of treatment with sunitinib or sorafenib. afinitor is indicated for the treatment of adult patients with renal angiomyolipoma and tsc, not requiring immediate surgery.

Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - everolimus 2,5 mg - tablet - 2,5 mg - everolimus 2.5 mg - everolimus

Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - everolimus 5 mg - tablet - 5 mg - everolimus 5 mg - everolimus

Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - everolimus 10 mg - tablet - 10 mg - everolimus 10 mg - everolimus

Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - everolimus 10 mg - tablet - 10 mg - everolimus 10 mg - everolimus

Belgia - engleză - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - everolimus 2,5 mg - tablet - 2,5 mg - everolimus 2.5 mg - everolimus